1. Home
  2. Stocks
  3. Natcopharm Share Price
  • Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Natco Pharma Share Price

    Large Cap
    ₹1,592.85
    + 0.9 (0.06%)
    13 September, 2024 06:54 BSE: 524816 NSE: NATCOPHARM ISIN: INE987B01026

    Start SIP in Natco Pharma

    Start SIP

    Natco Pharma Performance

    Day Range

    • Low 1,566
    • High 1,639
    ₹ 1,592

    52 Week Range

    • Low 724
    • High 1,639
    ₹ 1,592
    • Open Price1,605
    • Previous Close1,592
    • Volume1334511

    Natco Pharma Chart

    • Over 1 Month + 10.59%
    • Over 3 Month + 35.87%
    • Over 6 Month + 57.29%
    • Over 1 Year + 95.85%

    Natco Pharma Key Statistics

    P/E Ratio 17.4
    PEG Ratio 0.2
    Market Cap Cr
    Price to Book Ratio 4.9
    EPS 73.1
    Dividend 0.3
    Relative Strength Index 69.96
    Money Flow Index 79.16
    MACD Signal 53.92
    Average True Range 53.43

    Natco Pharma Investment Rating

    • Master Rating:

    • Natco Pharma has an operating revenue of Rs. 4,220.90 Cr. on a trailing 12-month basis. An annual revenue growth of 47% is outstanding, Pre-tax margin of 42% is great, ROE of 23% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 14% and 50% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 85 which is a GOOD score indicating consistency in earnings, a RS Rating of 82 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 56 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Natco Pharma Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,2379656259311,048781
    Operating Expenses Qtr Cr 474512387488545454
    Operating Profit Qtr Cr 763453238442504328
    Depreciation Qtr Cr 405240404038
    Interest Qtr Cr 454331
    Tax Qtr Cr 1228332647052
    Net Profit Qtr Cr 636349192360405254
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 3,6742,437
    Operating Expenses Annual Cr 1,9321,506
    Operating Profit Annual in Cr 1,637845
    Depreciation Cr 172151
    Interest Annual Cr 159
    Tax Annual Cr 249134
    Net Profit Annual Cr 1,307637
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 1,196784
    Cash from Investing Activity Annual Cr -961-437
    Cash from Financing Annual Activity Cr -237-347
    Net Cash Flow Annual Cr -11
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 5,5924,702
    Fixed Assets Annual Cr 2,4212,297
    Total Non Current Assets Annual Cr 3,1442,893
    Total Current Assets Annual Cr 3,4102,495
    Total Assets Annual Cr 6,5545,388
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 312258
    ROE Annual % 2314
    ROCE Annual % 2816
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 4940
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,3631,0687591,0311,141898
    Operating Expenses Qtr Cr 558571491573613559
    Operating Profit Qtr Cr 805497268458528339
    Depreciation Qtr Cr 445644444441
    Interest Qtr Cr 565443
    Tax Qtr Cr 1359144718049
    Net Profit Qtr Cr 669386213369420276
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 4,1272,812
    Operating Expenses Annual Cr 2,2471,772
    Operating Profit Annual in Cr 1,751936
    Depreciation Cr 187164
    Interest Annual Cr 1915
    Tax Annual Cr 285147
    Net Profit Annual Cr 1,388715
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 1,212849
    Cash from Investing Activity Annual Cr -1,033-477
    Cash from Financing Annual Activity Cr -247-363
    Net Cash Flow Annual Cr -689
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 5,8534,874
    Fixed Assets Annual Cr 2,5722,436
    Total Non Current Assets Annual Cr 2,8832,657
    Total Current Assets Annual Cr 4,0243,000
    Total Assets Annual Cr 6,9065,657
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 327267
    ROE Annual % 2415
    ROCE Annual % 2918
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 4738
    Invest in Natco Pharma

    Natco Pharma Technicals

    EMA & SMA

    Current Price
    ₹1,592.85
    + 0.9 (0.06%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹1,524.62
    • 50 Day
    • ₹1,415.01
    • 100 Day
    • ₹1,282.23
    • 200 Day
    • ₹1,126.10
    • 20 Day
    • ₹1,533.17
    • 50 Day
    • ₹1,397.72
    • 100 Day
    • ₹1,230.40
    • 200 Day
    • ₹1,060.89

    Natco Pharma Resistance and Support

    PIVOT
    ₹1,599.32
    Resistance
    First Resistance 1,632.53
    Second Resistance 1,672.22
    Third Resistance 1,705.43
    RSI 69.96
    MFI 79.16
    MACD Single Line 53.92
    MACD 49.72
    Support
    First Support 1,559.63
    Second Support 1,526.42
    Third Supoort 1,486.73

    Natco Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 1,417,145 47,630,243 33.61
    Week 1,095,104 38,744,772 35.38
    1 Month 1,092,683 41,456,380 37.94
    6 Month 999,261 44,227,298 44.26

    Natco Pharma Result Highlights

    Natco Pharma Synopsis

    NSE-Medical-Diversified

    Natco Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 2351.00 Cr. and Equity Capital is Rs. 36.50 Cr. for the Year ended 31/03/2023. Natco Pharma Ltd. is a Public Limited Listed company incorporated on 19/09/1981 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24230TG1981PLC003201 and registration number is 003201.
    Market Cap 28,513
    Sales 3,758
    Shares in Float 8.96
    No of funds 356
    Yield 0.35
    Book Value 5.1
    U/D Vol ratio 2.4
    LTDebt / Equity
    Alpha 0.2
    Beta 0.77

    Natco Pharma Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 49.71%49.71%49.71%49.71%
    Mutual Funds 2.67%4.08%5.2%7.65%
    Insurance Companies 5.09%5.58%6.04%6.34%
    Foreign Portfolio Investors 17.45%16.14%13.72%12.82%
    Financial Institutions/ Banks
    Individual Investors 21.59%20.61%21.24%19.5%
    Others 3.49%3.88%4.09%3.98%

    Natco Pharma Management

    Name Designation
    Mr. G S Murthy Chairman & Ind.Director
    Mr. V C Nannapaneni Managing Director
    Mr. Rajeev Nannapaneni Director & CEO
    Mr. T V Rao Independent Director
    Mr. D G Prasad Independent Director
    Dr. M U R Naidu Independent Director
    Dr. Leela Digumarti Independent Director
    Mr. P S R K Prasad Director & Exe. VP (Corp. Engg. Services)
    Dr. Linga Rao Donthineni Director & President (Tech. Affairs)
    Dr. Pavan Ganapati Bhat Director

    Natco Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Natco Pharma Corporate Action

    Date Purpose Remarks
    2024-08-12 Quarterly Results & Interim Dividend
    2024-05-27 Audited Results
    2024-02-14 Quarterly Results & Interim Dividend
    2023-11-14 Quarterly Results & Interim Dividend
    2023-08-09 Quarterly Results & Interim Dividend
    Date Purpose Remarks
    2024-08-23 INTERIM Rs.3.00 per share(150%)Interim Dividend
    2024-02-26 INTERIM Rs.1.25 per share(62.5%)Third Interim Dividend
    2023-11-24 INTERIM Rs.1.25 per share(62.5%)Second Interim Dividend
    2023-08-22 INTERIM Rs.7.00 per share(350%)Interim Dividend
    2023-02-21 INTERIM Rs.1.25 per share (62.5%) Third Interim Dividend

    Natco Pharma MF Shareholding

    Name Amount(cr)
    Mirae Asset Large & Midcap Fund Growth 39,706
    Canara Robeco Emerging Equities Growth 25,047
    SBI Magnum Midcap Fund Regular Growth 21,517
    Mirae Asset Midcap Fund Regular Growth 17,561
    Tata Equity P/E Fund Regular Growth 9,043

    Natco Pharma FAQs

    What is Share Price of Natco Pharma ?

    Natco Pharma share price is ₹1,592 As on 13 September, 2024 | 06:40

    What is the Market Cap of Natco Pharma ?

    The Market Cap of Natco Pharma is ₹28529.5 Cr As on 13 September, 2024 | 06:40

    What is the P/E ratio of Natco Pharma ?

    The P/E ratio of Natco Pharma is 17.4 As on 13 September, 2024 | 06:40

    What is the PB ratio of Natco Pharma ?

    The PB ratio of Natco Pharma is 4.9 As on 13 September, 2024 | 06:40

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of ₹10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.